Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Gains from Sales and Divestitures (2023 - 2024)

Kezar Life Sciences' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $9702.0 for Q3 2024.

  • For Q3 2024, Gains from Sales and Divestitures fell 92.25% year-over-year to $9702.0; the TTM value through Sep 2024 reached $9702.0, down 92.25%, while the annual FY2023 figure was $125188.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2024 was $9702.0 at Kezar Life Sciences, down from $22282.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $125188.0 in Q3 2023 and bottomed at $9702.0 in Q3 2024.